Background:
Sarcoids and squamous cell carcinomas (SCC) are the most concerning equine oncological diseases. Both tumors are challenging to manage due to their invasive behavior and high prevalence of recurrences. Furthermore, squamous cell carcinomas have propensity to metastasize. Programed cell-death ligand 1 (PD-L1) has been one of the main therapeutic targets for immunotherapy in various human tumors. PD-L1 research is equine tumors is scarce and more efforts are necessary to understand the potential of this biomarker as therapeutical target.
Aim:
Evaluate the immunohistochemical expression of PD-L1 in equine sarcoids and squamous cell carcinoma.
Methods:
Thirteen equine tumors (seven sarcoids and 6 squamous cell carcinomas) were tested by immunohistochemistry and evaluated semi quantitatively to assess the percentage of positive cells.
Results:
None of the sarcoids presented PD-L1 expression. Regarding squamous cell carcinoma, 2 tumors presented
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
